Drug Trial Radar · NCT04256421
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
490
Actual
Start
Feb 4, 2020
Primary completion
Sep 6, 2022
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be stratified by Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), LDH (\</= upper limit of normal \[ULN\] vs. \> ULN), and presence or history of brain metastasis (yes vs. no) and randomly assigned in a 1:1 ratio to receive one of the following treatment regimens during induction phase: * Arm A: Tiragolumab plus atezolizumab plus CE * Arm B: Placebo plus atezolizumab plus CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).
Conditions
- Small Cell Lung Cancer
Interventions
TiragolumabDrug
Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
AtezolizumabDrug
Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
CarboplatinDrug
Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
EtoposideDrug
Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
PlaceboDrug
Placebo administered by IV infusion on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)Time frame: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)
- Overall Survival (OS) in the PASTime frame: From randomization to death from any cause (up to approximately 24 months)
Locations
121 sites in 23 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers - Lone Tree
Lone Tree, Colorado
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
Washington D.C., District of Columbia
Florida Cancer Specialists
Fort Myers, Florida
SCRI Florida Cancer Specialists North
Sarasota, Florida
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia
Illinois Cancer Care
Peoria, Illinois
New England Cancer Specialists
Scarborough, Maine
Weinberg Cancer Institution at Franklin Square
Baltimore, Maryland
Minnesota Oncology Hematology
Minneapolis, Minnesota
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Broome Oncology - Binghamton
Binghamton, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Sarah Cannon Research Institute / Tennessee Oncology
Chattanooga, Tennessee
Sarah Cannon Research Inst.
Nashville, Tennessee
Texas Oncology Cancer Center
Austin, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Blue Ridge Cancer Care
Roanoke, Virginia
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.
Innsbruck, Austria
Klinik Penzing
Vienna, Austria
Krankenhaus Nord - Klinik Floridsdorf
Vienna, Austria
AZ St Maarten Campus Leopoldstr
Mechelen, Belgium
Clinique Ste-Elisabeth
Namur, Belgium
AZ Delta (Campus Rumbeke)
Roeselare, Belgium
Vitaz
Sint-Niklaas, Belgium
Oncocentro Serviços Médicos e Hospitalares Ltda
Fortaleza, Ceará, Brazil
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, Brazil
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Clínica de Oncologia Reichow
Blumenau, Santa Catarina, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Fakultni nemocnice Olomouc
Olomouc, Czechia
Vitkovicka Nemocnice Bma, A.S.
Ostrava, Czechia
Thomayerova nemocnice
Praha 4 - Krc, Czechia
Helios Klinikum Emil von Behring GmbH
Berlin, Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, Germany
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.